Loading clinical trials...
Loading clinical trials...
The objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.
The researchers aim to determine whether use of etonogestrel implant in patients with failed endometrial ablation significantly decreases hysterectomy rate. Changes in pelvic pain and vaginal bleeding will be assessed. Time to hysterectomy will be examined. The researchers hypothesize that treatment of failed endometrial ablation with etonogestrel implant will decrease pelvic pain and vaginal bleeding resulting in a significantly decreased need for hysterectomy.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
Yes
Saskatchewan Health Authority
Regina, Saskatchewan, Canada
Start Date
July 1, 2022
Primary Completion Date
April 30, 2024
Completion Date
April 30, 2024
Last Updated
November 25, 2025
Etonogestrel 68mg implant
DRUG
Etonogestrel 68mg implant
DEVICE
Lead Sponsor
Saskatchewan Health Authority - Regina Area
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06316583